Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

65.84
Delayed Data
As of 4:01pm ET
 +0.40 / +0.61%
Today’s Change
55.06
Today|||52-Week Range
68.12
+5.14%
Year-to-Date
Wall Street Weighs In on Athenahealth's Strategic Options
May 19 / TheStreet.com - Paid Partner Content
AbbVie Stock Lower on Humira Patent Ruling
May 17 / TheStreet.com - Paid Partner Content
What Drug Approval Means for Neurocrine Biosciences
May 19 / GuruFocus News - Paid Partner Content
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
May 16 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison ...
May 19 / Zacks.com - Paid Partner Content
AbbVie and J&J Present Positive Imbruvica Leukemia Data
May 15 / Zacks.com - Paid Partner Content
AbbVie's Humira Loses Patent in Coherus' Petitions
May 18 / GuruFocus News - Paid Partner Content
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
May 10 / Zacks.com - Paid Partner Content
New Stock Research Reports for Boeing, AbbVie and UnitedHealth
May 18 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
May 10 / Zacks.com - Paid Partner Content
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
May 18 / Zacks.com - Paid Partner Content